eIF1AY inhibitors represent a class of compounds that specifically target and inhibit the activity of the eukaryotic translation initiation factor 1A (eIF1A), which is essential in the initiation phase of protein synthesis. eIF1A plays a crucial role in stabilizing the binding of the initiator tRNA to the small ribosomal subunit and promoting the proper scanning of the messenger RNA (mRNA) for the start codon. By inhibiting eIF1A, these compounds disrupt the normal initiation process, leading to a decrease in overall protein synthesis. This inhibition can have significant effects on cellular processes, as protein synthesis is fundamental to cell growth, division, and response to environmental stimuli.
The mechanism of action of eIF1AY inhibitors involves binding to specific sites on the eIF1A protein, thereby preventing its interaction with the ribosomal subunits and other initiation factors. This binding can induce conformational changes in eIF1A, rendering it incapable of performing its function in the initiation complex. The development and study of eIF1AY inhibitors have provided valuable insights into the molecular dynamics of translation initiation and the regulatory mechanisms controlling protein synthesis. These compounds have also been used as tools in research to dissect the roles of eIF1A in various cellular pathways and to understand the broader implications of translational control in cellular physiology. The study of eIF1AY inhibitors continues to be a dynamic field, contributing to our understanding of the intricate processes that govern gene expression at the translational level.
VEJA TAMBÉM
Items 11 to 16 of 16 total
Mostrar:
Nome do Produto | CAS # | Numero de Catalogo | Quantidade | Preco | Uso e aplicacao | NOTAS |
---|---|---|---|---|---|---|
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Os danos no ADN causados pela doxorrubicina podem fazer com que a célula dê prioridade à reparação do ADN em detrimento das funções normais, suprimindo potencialmente a maquinaria de RNAi e diminuindo os níveis de eIF2C2. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
A inibição da topoisomerase I pela camptotecina&prime pode causar danos no ADN, o que pode levar a uma menor concentração nos processos de RNAi e, consequentemente, a uma menor expressão de eIF2C2. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Ao inibir a Hsp90, a Geldanamicina pode desestabilizar as proteínas associadas ao RNAi, o que pode incluir uma diminuição da estabilidade ou síntese do eIF2C2. | ||||||
Silvestrol | 697235-38-4 | sc-507504 | 1 mg | $920.00 | ||
Um composto natural isolado da planta Aglaia foveolata, conhecido pela sua potente inibição do EIF4AI. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $270.00 $465.00 $1607.00 $2448.00 $5239.00 | 4 | |
Outro composto natural encontrado em várias plantas, como as do género Aglaia, com forte atividade inibidora da EIF4AI. | ||||||
4E1RCat | 328998-25-0 | sc-361085 sc-361085A | 10 mg 50 mg | $189.00 $797.00 | ||
Um inibidor sintético de EIF4AI concebido para perturbar o complexo eIF4F, inibindo assim a tradução dependente de cap. |